HEALTHSTAT NEWS
STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect
Mwyngil Therapeutics, a new biotech startup, is developing obesity treatments without targeting the GLP-1 receptor, which most competitors use. CEO Luba Greenwood, a biotech veteran, emphasized the company's focus on non-GLP-1 approaches to avoid 'me too' drug development in the weight loss market.
Mentioned
Related Signal
Adjacent reporting
- An obesity drug deep-dive, and peptides move mainstream
- Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
- Experimental obesity drug outperforms traditional weight-loss treatments in early research
- STAT+: Investor Clive Meanwell on designing biotechs for population health, and AI’s role as a catalyst